NCT04775082Active, not recruitingPhase 3
A research study on how well liraglutide works in children with obesity
Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Feb 2026
Brief summary (registry, in English)
"To compare the effect of liraglutide 3.0 mg s.c. once daily versus placebo on weight management in children aged 6 to <12 years with obesity"
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 29 Dec 2023
- Start date
- 1 Mar 2021
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- EU CT number
- 2023-508504-38-00
- EudraCT number
- 2020-000546-34
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 21
- 6 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- Nothing written about Key Excl.
Who the study is looking for
- "Informed consent of parent(s) or legally acceptable representative of subject and child assent, as age-appropriate, obtained before any trial-related activities for the Main phase as well as for the Extension phase of the trial. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial"
- Male or female, aged 6 to <12 years at the time of signing informed consent
- Tanner stage 1-5 pubertal development at the time of signing informed consent
- BMI ≥95th percentile, on gender and age-specific growth charts (CDC.gov)
- History of failing to lose sufficient weight with lifestyle modification as judged by the investigator
- For T2D Haemoglobin A1c (HbA1c) ≤10.0% (86 mmol/mol) as measured by central laboratory at screening
Age in the registry: - to 17 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Brussel Coordinator of this site? Confirm its status | Jette | Belgium | Active, not recruiting |
| UZ Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Active, not recruiting |
| Hospital da Luz, S.A Coordinator of this site? Confirm its status | Lisbon | Portugal | Active, not recruiting |
| Centro Hospitalar Universitario De Lisboa Norte E.P.E. Coordinator of this site? Confirm its status | Lisbon | Portugal | Active, not recruiting |
| Hospital CUF Porto S.A. Coordinator of this site? Confirm its status | Porto | Portugal | Active, not recruiting |
| Centro Hospitalar Universitário de Santo Antonio,E.P.E. Coordinator of this site? Confirm its status | Porto | Portugal | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.